These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

526 related articles for article (PubMed ID: 35551665)

  • 1. Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematologic Malignancies.
    Hays P
    Cancer Treat Res; 2022; 183():287-315. PubMed ID: 35551665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.
    Goebeler ME; Bargou R
    Leuk Lymphoma; 2016 May; 57(5):1021-32. PubMed ID: 27050240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia.
    Le Jeune C; Thomas X
    Drug Des Devel Ther; 2016; 10():757-65. PubMed ID: 26937176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model.
    Meckler JF; Levis DJ; Vang DP; Tuscano JM
    Cancer Immunol Immunother; 2023 Sep; 72(9):2939-2948. PubMed ID: 37247022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cancer therapy using bispecific antibodies].
    Kadowaki N
    Rinsho Ketsueki; 2018; 59(10):1942-1947. PubMed ID: 30305495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.
    Viardot A; Locatelli F; Stieglmaier J; Zaman F; Jabbour E
    Ann Hematol; 2020 Oct; 99(10):2215-2229. PubMed ID: 32856140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extramedullary relapse and discordant CD19 expression between bone marrow and extramedullary sites in relapsed acute lymphoblastic leukemia after blinatumomab treatment.
    Demosthenous C; Lalayanni C; Iskas M; Douka V; Pastelli N; Anagnostopoulos A
    Curr Probl Cancer; 2019 Jun; 43(3):222-227. PubMed ID: 29895435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
    Aldoss I; Bargou RC; Nagorsen D; Friberg GR; Baeuerle PA; Forman SJ
    Leukemia; 2017 Apr; 31(4):777-787. PubMed ID: 28028314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia.
    Wu J; Fu J; Zhang M; Liu D
    J Hematol Oncol; 2015 Sep; 8():104. PubMed ID: 26337639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blinatumomab for the treatment of adult acute lymphoblastic leukemia.
    Dahl J; Mace M; Kantarjian H; Jabbour E
    Drugs Today (Barc); 2015 Apr; 51(4):231-41. PubMed ID: 26020065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blinatumomab: Bridging the Gap in Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.
    Folan SA; Rexwinkle A; Autry J; Bryan JC
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S2-5. PubMed ID: 27521320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.
    Tapia-Galisteo A; Álvarez-Vallina L; Sanz L
    J Hematol Oncol; 2023 Jul; 16(1):83. PubMed ID: 37501154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and future role of bispecific T-cell engagers in pediatric acute lymphoblastic leukemia.
    Algeri M; Del Bufalo F; Galaverna F; Locatelli F
    Expert Rev Hematol; 2018 Dec; 11(12):945-956. PubMed ID: 30358451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types.
    Einsele H; Borghaei H; Orlowski RZ; Subklewe M; Roboz GJ; Zugmaier G; Kufer P; Iskander K; Kantarjian HM
    Cancer; 2020 Jul; 126(14):3192-3201. PubMed ID: 32401342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals.
    Philipp N; Kazerani M; Nicholls A; Vick B; Wulf J; Straub T; Scheurer M; Muth A; Hänel G; Nixdorf D; Sponheimer M; Ohlmeyer M; Lacher SM; Brauchle B; Marcinek A; Rohrbacher L; Leutbecher A; Rejeski K; Weigert O; von Bergwelt-Baildon M; Theurich S; Kischel R; Jeremias I; Bücklein V; Subklewe M
    Blood; 2022 Sep; 140(10):1104-1118. PubMed ID: 35878001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Bispecific antibodies in onco-hematology: Applications and perspectives].
    Barrière S; El-Ghazzi N; Garcia M; Guièze R
    Bull Cancer; 2021 Oct; 108(10S):S195-S204. PubMed ID: 34920803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bispecific antibodies in haematological malignancies.
    Viardot A; Bargou R
    Cancer Treat Rev; 2018 Apr; 65():87-95. PubMed ID: 29635163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.
    DasGupta RK; Marini BL; Rudoni J; Perissinotti AJ
    J Oncol Pharm Pract; 2018 Sep; 24(6):453-467. PubMed ID: 28583018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer.
    Stieglmaier J; Benjamin J; Nagorsen D
    Expert Opin Biol Ther; 2015; 15(8):1093-9. PubMed ID: 25971805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.
    Ribera JM
    Expert Rev Hematol; 2017 Dec; 10(12):1057-1067. PubMed ID: 29082835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.